Basilea provides portfolio update and outlook

About this update from Basilea Pharmaceutica Ag

Allschwil, Switzerland, January 08, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress within its R&D and commercial portfolio during 2025 and outlined the upcoming milestones and timelines . David Veitch, Chief Executive Officer, highlighted: "We entered 2025 from a position of strength and closed the year even stronger, thanks to outstanding execution and significant progress across all fronts. During 2025, we delivered on every goal we set.” He continued: “Cresemba celebrated its 10th year on the market with continued commercial success, achieving strong global in-market sales and expanding its reach to more than 75 countries. Zevtera was successfully launched in the US, its commercially most important market, while our R&D pipeline advanced toward next milestones. This included fosmanogepix entering its second phase 3 study and the in-licensing of ceftibuten-ledaborbactam, a novel oral antibiotic for complicated urinary tract infections (cUTI). These programs are designed to drive medium-term growth and are progressing fully in line with our plan.” He concluded: “Our business model is anchored in strong partnerships. Recently, we forged two new collaborations in preclinical development: one focused on artificial intelligence (AI)-driven antibacterial drug design and the other on antifungal drug development. These partnerships combine our expertise in anti-infectives with our partners’ specialized capabilities to strengthen our early-stage pipeline. At the same time, existing partnerships remained robust. We secured substantial non-dilutive funding through the Other Transactions Agreement (OTA) with the Biomedical Advanced Research and Development Authority (BARDA) [ 1 ] for our antifungals fosmanogepix and BAL2062, and a prior BARDA contract was novated to Basilea following the in-licensing of the antibiotic ceftibuten-ledaborbactam. Commercial partnerships also delivered multiple milestone payments from Europe, China/Asia-Pacific, and Japan, underscoring the success of our commercial products as they address patients’ needs worldwide.” Portfolio key highlights 2025 and outlook 2026 Cresemba ® (isavuconazole): Reinforcing position as global market leader by value Zevtera ® (ceftobiprole): Establishing a novel treatment option for Staphylococcus aureus bacteremia (SAB) in the US Fosmanogepix: Advancing phase 3 program in invasive mold and yeast infections Ceftibuten-ledaborbactam: addressing unmet needs in cUTI Early-stage pipeline programs: Completed preclinical profiling and advancing toward next inflection points New R&D partnerships: Driving long-term value creation In December and January, we entered into two collaborations aimed at accelerating innovation and strengthening our early-stage pipeline with high-potential drug candidates to support long-term growth: About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com . Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: This press release can be downloaded from www.basilea.com . References Attachment

View stock analysis, news, and events for Basilea Pharmaceutica Ag